EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Viktor Grünwald iD, Rana R McKay, Tomas Buchler, Masatoshi Eto, Se Hoon Park iD, Toshio Takagi, Sylvie Zanetta, Daniel Keizman iD, Cristina Suárez, Sylvie Négrier, Jae Lyun Lee, Daniele Santini und 9 weitere

International Journal of Cancer · 2025-04 · 156 (7) · 1326-1335

DOI: 10.1002/ijc.35288 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 30.12.2024. Verfasst von Viktor Grünwald und 20 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Phenylurea Compounds, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Eisai Inc., Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc analysis of tumor response data based on baseline metastatic characteristics of patients who received lenvatinib plus pembrolizumab versus sunitinib, at the final overall survival analysis time point of CLEAR (cutoff: July 31, 2022). Treatment‐naïve adults with aRCC were randomized to: lenvatinib (20 mg PO QD in 21‐day cycles) plus pembrolizumab ( n = 355; 200 mg IV Q3W); lenvatinib plus everolimus (not reported here); or sunitinib ( n = 357; 50 mg PO QD; 4 weeks on/2 weeks off). The most common (lenvatinib plus pembrolizumab; sunitinib, respectively) metastatic site was lung (71.0%; 63.9%), followed by lymph node (45.6%; 43.7%), bone (22.5%; 24.9%), and liver (17.7%; 19.6%). Across treatment arms, ≥65% had two or more metastatic organs/sites involved, >80% of patients had nontarget lesions, and ~45% had baseline sums of diameters of target lesions ≥60 mm. Lenvatinib plus pembrolizumab demonstrated greater progression‐free survival, objective response rate, and duration of response versus sunitinib across evaluable subgroups regardless of site or size of baseline metastasis or number of metastatic sites at baseline. Overall survival generally trended to favor lenvatinib plus pembrolizumab versus sunitinib; and tumor shrinkage was greater across sites (lung, lymph node, liver, and bone) for patients in the lenvatinib‐plus‐pembrolizumab arm versus the sunitinib arm. These results further support lenvatinib plus pembrolizumab as a standard‐of‐care in patients with aRCC regardless of site or size of baseline metastasis or the number of metastatic sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsPhenylurea CompoundsAntibodies, Monoclonal, HumanizedSunitinibQuinolinesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeNeoplasm Metastasis

Stichwörter der Autor:innen

lenvatiniblenvatinib plus pembrolizumabpembrolizumabrenal cell carcinoma

Substanzen

lenvatinibPhenylurea CompoundsAntibodies, Monoclonal, HumanizedpembrolizumabSunitinibQuinolines

Autor:innen und Institutionen

  • Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany.
  • Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA.
  • Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.
  • Department of Urology, Kyushu University, Fukuoka, Japan.
  • Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

ORCID-Profile: Viktor Grünwald, Se Hoon Park, Daniel Keizman, Michael Staehler

Förderung

  • NCI NIH HHS
  • Eisai Inc.
  • Merck Sharp & Dohme LLC
  • Eisai Canada
  • Memorial Sloan-Kettering Cancer Center

Zitieren

APA

Grünwald, V., McKay, R. R., Buchler, T., Eto, M., Park, S. H., Takagi, T., Zanetta, S., Keizman, D., Suárez, C., Négrier, S., Lee, J. L., Santini, D., Bedke, J., Staehler, M., Kollmannsberger, C., Choueiri, T. K., Motzer, R. J., Burgents, J. E., Xie, R., …, & Powles, T. (2025). Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. International Journal of Cancer, 156(7), 1326-1335. https://doi.org/10.1002/ijc.35288

Vancouver

Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, et al. Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. International Journal of Cancer. 2025;156(7):1326-1335. doi:10.1002/ijc.35288

BibTeX
@article{Grnwald2025,
  author = {Grünwald, Viktor and McKay, Rana R and Buchler, Tomas and Eto, Masatoshi and Park, Se Hoon and Takagi, Toshio and Zanetta, Sylvie and Keizman, Daniel and Suárez, Cristina and Négrier, Sylvie and Lee, Jae Lyun and Santini, Daniele and Bedke, Jens and Staehler, Michael and Kollmannsberger, Christian and Choueiri, Toni K and Motzer, Robert J and Burgents, Joseph E and Xie, Ran and Okpara, Chinyere E and Powles, Thomas},
  title = {Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {156},
  number = {7},
  pages = {1326--1335},
  doi = {10.1002/ijc.35288}
}
Kostenlos starten →